Nanjing Legend Biotech Co.

This early-stage study tests an experimental cell therapy called LUCAR-DKS1 in 36 adults whose autoimmune diseases (like lupus or vasculitis) have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will monitor side effec…

This study tests a new treatment called LUCAR-G79 for people with autoimmune diseases like lupus that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack disease-causing cells. The goal is to see if it is safe a…

This early-stage study tests a new treatment called LUCAR-G79D for adults with lupus or inflammatory myopathies that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack disease-causing cells. The main goals are …

This study tests a new treatment called LCAR-F33S for people with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals are to check safety and find the best d…